Hyperphosphataemia after Velagliflozin (Senvelgo) in cats
The FDA has received 79 reports of hyperphosphataemia in cats after Velagliflozin. That is 1.6% of all reports for this medicine, compared with 1.0% across reports for all cat medicines, so it is reported unusually often with this medicine.
79Reports
57%Marked serious
0.0%Recovered
34%Died or euthanised
11 daysTypical onset
Sponsored
How soon it started
How the animals did
Problems reported at the same time
Age of the animals
About this medicine
Velagliflozin treats diabetes in cats (oral, an SGLT2 inhibitor).
Products with this ingredient include Senvelgo. The FDA hides brand names in its public data, so these reports cover every product with the same active ingredients.
Questions owners ask
- Can Velagliflozin cause hyperphosphataemia in cats?
- 79 reports link the two, but a report alone does not prove the medicine was the cause: other illnesses, other medicines or coincidence can be involved. Your vet can judge it for your animal.
- How soon after a dose was it reported?
- In half of the reports with dates, it started within 11 days of the first dose.
- What should I do?
- Don't give another dose until you've spoken to your vet, and keep the packaging so you can tell them the product and dose. Your vet can also report it to the FDA (or you can, through the manufacturer or FDA form 1932a).
Hyperphosphataemia with similar medicines
- Hyperphosphataemia after Bexagliflozin (Bexacat) 73 reports · 1.8% of its reports
- Hyperphosphataemia after Insulin 25 reports · 0.7% of its reports
- Hyperphosphataemia after Methimazole 20 reports · 1.1% of its reports
All reported side effects of Velagliflozin in cats · Medicines most reported with hyperphosphataemia